REG-BARCLAYS PLC Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD
. Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)
1. KEY INFORMATION
| (a) | Full name of discloser: | Barclays PLC. | |||
| (b) | Owner or controller of interest and short | ||||
| positions disclosed, if different from 1(a): | |||||
| (c) | Name of offeror/offeree in relation to whose | TAKEDA PHARMACEUTICAL CO LTD | |||
| relevant securities this form relates: | |||||
| (d) | If an exempt fund manager connected with an | ||||
| offeror/offeree, state this and specify identity of | |||||
| offeror/offeree: | |||||
| (e) | Date position held/dealing undertaken: | 30 August 2018 | |||
| (f) | In addition to the company in 1(c) above, is the discloser making | YES: | |||
| disclosures in respect of any other party to the offer? | SHIRE PLC |
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
| Class of relevant security: | Ordinary NPV | ||||||||||
| Interests | Short Positions | ||||||||||
| Number | (%) | Number | (%) | ||||||||
| (1) | Relevant securities owned | ||||||||||
| and/or controlled: | 11,430,741 | 1.44% | 12,521,124 | 1.58% | |||||||
| (2) | Cash-settled derivatives: | ||||||||||
| 18,479,090 | 2.33% | 16,983,300 | 2.14% | ||||||||
| (3) | Stock-settled derivatives (including options) | ||||||||||
| and agreements to purchase/sell: | 16,893,700 | 2.13% | 17,313,700 | 2.18% | |||||||
| (4) | |||||||||||
| TOTAL: | 46,803,531 | 5.89% | 46,818,124 | 5.89% | |||||||
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors’ and other employee options)
| Class of relevant security in relation to which subscription right exists: | |
| Details, including nature of the rights concerned and relevant percentages: |
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
| Class of relevant | Purchase/sale | Number of | Price per unit | ||||
| security | securities | ||||||
| ADR | Purchase | 29,133 | 20.7055 USD | ||||
| ADR | Sale | 29,133 | 20.7054 USD | ||||
| Ordinary NPV | Purchase | 100 | 4,625.0000 JPY | ||||
| Ordinary NPV | Purchase | 100 | 4,617.0000 JPY | ||||
| Ordinary NPV | Purchase | 200 | 4,613.5000 JPY | ||||
| Ordinary NPV | Purchase | 300 | 4,621.0000 JPY | ||||
| Ordinary NPV | Purchase | 400 | 4,601.5000 JPY | ||||
| Ordinary NPV | Purchase | 500 | 4,605.6000 JPY | ||||
| Ordinary NPV | Purchase | 500 | 4,605.4000 JPY | ||||
| Ordinary NPV | Purchase | 500 | 4,615.2000 JPY | ||||
| Ordinary NPV | Purchase | 700 | 4,606.1285 JPY | ||||
| Ordinary NPV | Purchase | 800 | 4,612.7500 JPY | ||||
| Ordinary NPV | Purchase | 1,500 | 4,605.8666 JPY | ||||
| Ordinary NPV | Purchase | 2,600 | 4,603.1923 JPY | ||||
| Ordinary NPV | Purchase | 5,200 | 4,612.8442 JPY | ||||
| Ordinary NPV | Purchase | 5,200 | 4,603.6538 JPY | ||||
| Ordinary NPV | Purchase | 5,600 | 4,624.0000 JPY | ||||
| Ordinary NPV | Purchase | 5,800 | 4,612.1896 JPY | ||||
| Ordinary NPV | Purchase | 6,100 | 4,609.1491 JPY | ||||
| Ordinary NPV | Purchase | 7,200 | 4,608.0000 JPY | ||||
| Ordinary NPV | Purchase | 7,700 | 4,627.6753 JPY | ||||
| Ordinary NPV | Purchase | 10,500 | 4,615.2285 JPY | ||||
| Ordinary NPV | Purchase | 11,200 | 4,612.9464 JPY | ||||
| Ordinary NPV | Purchase | 12,300 | 4,602.0000 JPY | ||||
| Ordinary NPV | Purchase | 48,400 | 4,617.8533 JPY | ||||
| Ordinary NPV | Purchase | 109,600 | 4,614.6961 JPY | ||||
| Ordinary NPV | Purchase | 273,800 | 4,611.2140 JPY | ||||
| Ordinary NPV | Sale | 24 | 4,626.5416 JPY | ||||
| Ordinary NPV | Sale | 74 | 4,619.4864 JPY | ||||
| Ordinary NPV | Sale | 200 | 4,613.5000 JPY | ||||
| Ordinary NPV | Sale | 292 | 4,605.5719 JPY | ||||
| Ordinary NPV | Sale | 294 | 4,615.7414 JPY | ||||
| Ordinary NPV | Sale | 500 | 4,609.4000 JPY | ||||
| Ordinary NPV | Sale | 500 | 4,605.6000 JPY | ||||
| Ordinary NPV | Sale | 739 | 4,604.1299 JPY | ||||
| Ordinary NPV | Sale | 758 | 4,613.4604 JPY | ||||
| Ordinary NPV | Sale | 800 | 4,612.7500 JPY | ||||
| Ordinary NPV | Sale | 852 | 4,614.2758 JPY | ||||
| Ordinary NPV | Sale | 1,117 | 4,613.6526 JPY | ||||
| Ordinary NPV | Sale | 1,193 | 4,618.1332 JPY | ||||
| Ordinary NPV | Sale | 1,400 | 4,616.5357 JPY | ||||
| Ordinary NPV | Sale | 1,448 | 4,614.4530 JPY | ||||
| Ordinary NPV | Sale | 2,000 | 4,605.7500 JPY | ||||
| Ordinary NPV | Sale | 2,200 | 4,603.6136 JPY | ||||
| Ordinary NPV | Sale | 2,600 | 4,603.1923 JPY | ||||
| Ordinary NPV | Sale | 3,900 | 4,612.2717 JPY | ||||
| Ordinary NPV | Sale | 4,000 | 4,600.0000 JPY | ||||
| Ordinary NPV | Sale | 4,400 | 4,610.8068 JPY | ||||
| Ordinary NPV | Sale | 4,900 | 4,611.2040 JPY | ||||
| Ordinary NPV | Sale | 5,600 | 4,603.5000 JPY | ||||
| Ordinary NPV | Sale | 5,900 | 4,612.0474 JPY | ||||
| Ordinary NPV | Sale | 6,109 | 4,620.0308 JPY | ||||
| Ordinary NPV | Sale | 7,400 | 4,601.0000 JPY | ||||
| Ordinary NPV | Sale | 8,400 | 4,600.2857 JPY | ||||
| Ordinary NPV | Sale | 8,400 | 4,609.2142 JPY | ||||
| Ordinary NPV | Sale | 10,600 | 4,613.6226 JPY | ||||
| Ordinary NPV | Sale | 10,700 | 4,602.0000 JPY | ||||
| Ordinary NPV | Sale | 28,100 | 4,601.1743 JPY | ||||
| Ordinary NPV | Sale | 28,400 | 4,609.1654 JPY | ||||
| Ordinary NPV | Sale | 32,000 | 4,610.9375 JPY | ||||
| Ordinary NPV | Sale | 109,300 | 4,614.0118 JPY | ||||
| Ordinary NPV | Sale | 237,500 | 4,614.3604 JPY |
(b) Cash-settled derivative transactions
| Class of | Product | Nature of dealing | Number of | Price per | |||||
| relevant | description | reference | unit | ||||||
| security | securities | ||||||||
| Ordinary NPV | SWAP | Long | 24 | 4,626.5373 JPY | |||||
| Ordinary NPV | SWAP | Long | 29 | 4,619.2621 JPY | |||||
| Ordinary NPV | SWAP | Long | 45 | 4,619.6268 JPY | |||||
| Ordinary NPV | SWAP | Long | 123 | 4,615.8933 JPY | |||||
| Ordinary NPV | SWAP | Long | 124 | 4,606.0796 JPY | |||||
| Ordinary NPV | SWAP | Long | 168 | 4,605.1944 JPY | |||||
| Ordinary NPV | SWAP | Long | 171 | 4,615.6329 JPY | |||||
| Ordinary NPV | SWAP | Long | 306 | 4,604.1792 JPY | |||||
| Ordinary NPV | SWAP | Long | 318 | 4,613.5433 JPY | |||||
| Ordinary NPV | SWAP | Long | 378 | 4,614.9041 JPY | |||||
| Ordinary NPV | SWAP | Long | 433 | 4,604.0964 JPY | |||||
| Ordinary NPV | SWAP | Long | 440 | 4,613.4002 JPY | |||||
| Ordinary NPV | SWAP | Long | 453 | 4,613.6626 JPY | |||||
| Ordinary NPV | SWAP | Long | 474 | 4,613.7755 JPY | |||||
| Ordinary NPV | SWAP | Long | 488 | 4,618.1472 JPY | |||||
| Ordinary NPV | SWAP | Long | 584 | 4,614.5011 JPY | |||||
| Ordinary NPV | SWAP | Long | 664 | 4,613.6453 JPY | |||||
| Ordinary NPV | SWAP | Long | 705 | 4,618.1234 JPY | |||||
| Ordinary NPV | SWAP | Long | 864 | 4,614.4206 JPY | |||||
| Ordinary NPV | SWAP | Long | 2,387 | 4,620.5374 JPY | |||||
| Ordinary NPV | SWAP | Long | 3,722 | 4,619.7057 JPY | |||||
| Ordinary NPV | SWAP Expires 18/09/2018 | Long | 127,000 | 4,600.0000 JPY | |||||
| Ordinary NPV | CFD | Short | 4,000 | 4,630.4630 JPY | |||||
| Ordinary NPV | SWAP Expires 18/12/2018 | Short | 127,000 | 4,600.0000 JPY |
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
| Class of relevant security | Product description e.g. call option | Writing, purchasing, selling, varying etc. | Number of securities to which option relates | Exercise price per unit |
Type
e.g. American, European etc. |
Expiry date | Option money paid/ received per unit |
(ii) Exercise
| Class of relevant security |
Product description
e.g. call option |
Exercising/ exercised against | Number of securities | Exercise price per unit |
(d) Other dealings (including subscribing for new securities)
| Class of relevant security |
Nature of dealing
e.g. subscription, conversion |
Details | Price per unit (if applicable) |
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
|
Details of any indemnity or option arrangement, or any agreement or
understanding, formal or informal, relating to relevant securities
which may be an inducement to deal or refrain from dealing entered
into by the person making the disclosure and any party to the offer
or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” |
|
None |
(b) Agreements, arrangements or understandings relating to options or derivatives
|
Details of any agreement, arrangement or understanding, formal or
informal, between the person making the disclosure and any other
person relating to:
(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none” |
|
None |
(c) Attachments
| Is a Supplemental Form 8 (Open Positions) attached? | YES | ||
| Date of disclosure: | 31 Aug 2018 | ||
| Contact name: | Large Holdings Regulatory Operations | ||
| Telephone number: | 020 3134 7213 |
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
SUPPLEMENTAL FORM 8 (OPEN POSITIONS)
DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.
Note 5(i) on Rule 8 of the Takeover Code (the “Code”)
1. KEY INFORMATION
| Identity of the person whose positions/dealings | Barclays PLC. | ||
| are being disclosed: | |||
| Name of offeror/offeree in relation to whose | TAKEDA PHARMACEUTICAL CO LTD | ||
| relevant securities this from relates: |
2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)
| Class | Product | Writing, | Number | Exercise | Type | Expiry | |||||||
| of | description | purchasing, | of | price | date | ||||||||
| relevant | selling, | securities | per unit | ||||||||||
| security | varying etc | to which | |||||||||||
| option | |||||||||||||
| relates | |||||||||||||
| Ordinary NPV | Call Options | Purchased | 39,000 | 5781.0000 | European | 14 Dec 2018 | |||||||
| Ordinary NPV | Call Options | Purchased | 40,000 | 6182.0000 | European | 14 Dec 2018 | |||||||
| Ordinary NPV | Call Options | Purchased | 48,000 | 4625.0000 | European | 12 Oct 2018 | |||||||
| Ordinary NPV | Call Options | Written | -460,000 | 6182.0000 | European | 14 Dec 2018 | |||||||
| Ordinary NPV | Call Options | Written | -114,000 | 4750.0200 | European | 14 May 2019 | |||||||
| Ordinary NPV | Call Options | Written | -104,700 | 5065.8300 | European | 17 Apr 2019 | |||||||
| Ordinary NPV | Call Options | Written | -78,000 | 5781.0000 | European | 14 Dec 2018 | |||||||
| Ordinary NPV | Call Options | Written | -70,000 | 4598.0000 | European | 14 Jun 2019 | |||||||
| Ordinary NPV | Put Options | Purchased | -48,000 | 4625.0000 | European | 12 Oct 2018 | |||||||
| Ordinary NPV | Put Options | Purchased | -39,000 | 5781.0000 | European | 14 Dec 2018 | |||||||
| Ordinary NPV | Put Options | Written | 70,000 | 4598.0000 | European | 14 Jun 2019 | |||||||
| Ordinary NPV | Put Options | Written | 78,000 | 5781.0000 | European | 14 Dec 2018 | |||||||
| Ordinary NPV | Put Options | Written | 104,700 | 5065.8300 | European | 17 Apr 2019 | |||||||
| Ordinary NPV | Put Options | Written | 114,000 | 4750.0200 | European | 14 May 2019 | |||||||
| Ordinary NPV | Call Options | Purchased | 3,200,000 | 4651.0142 | European | 5 Sep 2018 | |||||||
| Ordinary NPV | Call Options | Purchased | 13,200,000 | 4799.0427 | European | 5 Sep 2018 | |||||||
| Ordinary NPV | Call Options | Written | -13,200,000 | 4799.0427 | European | 5 Sep 2018 | |||||||
| Ordinary NPV | Call Options | Written | -3,200,000 | 4651.0142 | European | 5 Sep 2018 | |||||||
| Ordinary NPV | Put Options | Purchased | -13,200,000 | 4799.0427 | European | 5 Sep 2018 | |||||||
| Ordinary NPV | Put Options | Purchased | -3,200,000 | 4651.0142 | European | 5 Sep 2018 | |||||||
| Ordinary NPV | Put Options | Written | 3,200,000 | 4651.0142 | European | 5 Sep 2018 | |||||||
| Ordinary NPV | Put Options | Written | 13,200,000 | 4799.0427 | European | 5 Sep 2018 |
3. AGREEMENTS TO PURCHASE OR SELL ETC.
| Full details should be given so that the nature of the interest or position can be fully understood: |
It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.
The currency of all prices and other monetary amounts should be stated.
The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180831005210/en/
BARCLAYS PLC
Recent news on Takeda Pharmaceutical Co
See all newsREG - Malin Corp PLC - Malin Announces 2021 Full Year Results
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Confirmation of post-offer intention statements
AnnouncementREG - Morgan Stanley&CoLLC Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI) - Replacement of Takeda
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Statement re Applicable Exchange Rate
AnnouncementREG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - Replacement of Takeda
Announcement